Metoprolol Succinate Tablet, Film Coated, Extended Release
Product Images NDC 50268-540

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Metoprolol Succinate (NDC 50268-540). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Avpak, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label 1 (Label 5026854015 2018.07)

Metoprolol succinate 25 mg extended-release tablets USP in film-coated oral tablet form. The label indicates a unit dose package of 50 tablets (5 blister packs of 10 tablets each). Manufactured for AvKARE, Inc., Pulaski, TN. The label includes storage instructions and a warning to keep out of reach of children, with the product name and dosage prominently displayed twice along with the NDC 50268-540-15.*

FDA Label Image

Label 2 (Label 5026854115 2018.07)

Metoprolol succinate extended-release tablets USP 50 mg film-coated, oral dosage form. The label indicates 50 tablets in unit dose packaging (5 x 10). Manufactured for AvPAK, Pulaski, Tennessee, with storage instructions and warnings. This label features the AvPAK logo and a barcode.*

FDA Label Image

Label 3 (Label 5026854215 2018.07)

Label for Metoprolol succinate extended-release tablets USP 100 mg, oral film-coated tablets, extended-release, available in a unit dose package of 50 tablets (5 x 10). The label includes NDC 50268-542-15, Rx only designation, storage instructions at 20°-25°C, manufacturer AvPAK in Pulaski, TN, and warnings to keep out of reach of children.*

FDA Label Image

Label 4 (Label 5026854315 2018.07)

Label for Metoprolol succinate extended-release tablets USP, 200 mg strength. The label shows the product is by AvPAK and contains 50 tablets (5 blister packs of 10). It includes dosage form as film-coated extended-release tablets, oral route, Rx only, and storage instructions at 20°-25°C (68°-77°F). A barcode and warning to keep out of children are also visible.*

FDA Label Image

Figure (Figure)

A forest plot chart titled 'Results for Subgroups in MERIT-HF' showing relative risk and 95% confidence intervals for various subgroups. The chart compares the effects of metoprolol succinate extended-release tablets versus placebo on total mortality, total mortality or all-cause hospitalization (time to first event), and total mortality or hospitalization for heart failure (time to first event). Subgroups include U.S. and non-U.S. patients, NYHA classes II-IV, ejection fraction ranges, ischemic etiology, sex, race, prior myocardial infarction, diabetes, hypertension, and heart rate categories.*

FDA Label Image

Structure (Structure)

Chemical structure of metoprolol succinate showing the molecular arrangement of its functional groups, including hydroxy, methoxy, and succinate components, displayed in a skeletal formula format.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.